As a pandemic-weary country confronts another wave of COVID-19 cases with a strained health care system, Health Canada is looking at new products that could offer some relief: antivirals.
Two such drugs are making their way through the labyrinthine Health Canada approvals process: Pfizer’s Paxlovid and Merck’s molnupiravir.
These antiviral treatments, which are prescribed by a doctor and administered in pill form, are designed to help the body fight off the SARS-CoV-2 virus, reduce symptoms from an infection and shorten the period of illness.
While Merck has grappled with questions about the efficacy of its product — molnupiravir is said to reduce hospitalization or death by 30 per cent — Paxlovid earned especially high marks
→ Continue reading at CBC News